Announcement of Resolutions of the Second Extraordinary Meeting of the 6th Board of Directors of Fangsheng Pharmaceutical in 2026
Hunan Nansheng Pharmaceutical Co., Ltd.
HUNANFANGSHENGPHARMACEUTICALCO.,LTD.
Securities code: 603998 Securities abbreviation: Fangsheng Pharmaceutical Announcement number: 2026-037
Hunan Nansheng Pharmaceutical Co., Ltd.
Announcement of the Resolutions of the Second Extraordinary Meeting of the Sixth Board of Directors in 2026
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
The second extraordinary meeting of the sixth session of the Board of Directors of Hunan Nansheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") in 2026 was held at 10:00 am on June 6, 2026 in the conference room (1) on the first floor of the company's office building by a combination of on-site and communication voting. The company’s Securities Department has notified all directors via email, WeChat, phone, etc. on June 3, 2026. This meeting was convened by Chairman Ms. Zhou Xiaoli. Six directors should be present at the meeting, but actually six directors were present (independent directors Mr. Gao Xuemin, Ms. Du Shouying and Mr. Yuan Xiong attended the meeting via live connection). The number of voting participants and the convening and convening procedures of this meeting complied with the relevant provisions of the Company Law and the Articles of Association, and the meeting was legal and valid. The meeting reviewed and approved the following proposals:
- Proposal on adding new related parties and increasing the estimated amount of daily related transactions in 2026
This proposal has been reviewed and approved at a special meeting of the company's independent directors and agreed to be submitted to the board of directors for review.
For details, please refer to the company’s announcement No. 2026-038 published on the website of the Shanghai Stock Exchange (www.sse.com.cn) and the Securities Times, Shanghai Securities News, China Securities News and Securities Daily.
The voting results of this motion: 3 votes in favor, 0 votes against, 0 abstentions, and the vote was passed. Related directors Ms. Zhou Xiaoli, Mr. Chen Bo and Mr. Xiao Yue abstained from voting.
2. Proposal on increasing capital to wholly-owned subsidiaries
This proposal has been reviewed and approved by the Strategy and ESG Committee of the Company’s Board of Directors and agreed
Page 1 of 2
Hunan Nansheng Pharmaceutical Co., Ltd.
HUNANFANGSHENGPHARMACEUTICALCO.,LTD.
Submit to the Board of Directors for consideration.
For details, please refer to the company’s announcement No. 2026-039 published on the website of the Shanghai Stock Exchange (www.sse.com.cn) and the Securities Times, Shanghai Securities News, China Securities News and Securities Daily.
The voting results of this motion: 6 votes in favor, 0 votes against, 0 abstentions, and the vote was passed. Announcement hereby
Board of Directors of Hunan Nansheng Pharmaceutical Co., Ltd. June 8, 2026
Page 2 of 2